566 related articles for article (PubMed ID: 26548828)
1. Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States.
Jethwa PR; Patel TD; Hajart AF; Eloy JA; Couldwell WT; Liu JK
World Neurosurg; 2016 Mar; 87():65-76. PubMed ID: 26548828
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Endoscopic Versus Microscopic Transsphenoidal Surgery for Pituitary Adenoma.
Ament JD; Yang Z; Khatchadourian V; Strong EB; Shahlaie K
World Neurosurg; 2018 Feb; 110():e496-e503. PubMed ID: 29158096
[TBL] [Abstract][Full Text] [Related]
3. Update on prolactinomas. Part 2: Treatment and management strategies.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
[TBL] [Abstract][Full Text] [Related]
4. [Cost-effectiveness analysis of two therapeutic methods for prolactinoma].
Zhen JR; Yu Q; Zhang YH; Ma WB; Lin SQ
Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):257-61. PubMed ID: 18843964
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the endoscopic versus microscopic approach for pituitary adenoma resection.
Rudmik L; Starreveld YP; Vandergrift WA; Banglawala SM; Soler ZM
Laryngoscope; 2015 Jan; 125(1):16-24. PubMed ID: 24938934
[TBL] [Abstract][Full Text] [Related]
6. Hyperprolactinemia in children: clinical features and long-term results.
Catli G; Abaci A; Altincik A; Demir K; Can S; Buyukgebiz A; Bober E
J Pediatr Endocrinol Metab; 2012; 25(11-12):1123-8. PubMed ID: 23329759
[TBL] [Abstract][Full Text] [Related]
7. THERAPY OF ENDOCRINE DISEASE: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature.
Tampourlou M; Trifanescu R; Paluzzi A; Ahmed SK; Karavitaki N
Eur J Endocrinol; 2016 Sep; 175(3):R89-96. PubMed ID: 27207245
[TBL] [Abstract][Full Text] [Related]
8. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
10. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
11. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
[TBL] [Abstract][Full Text] [Related]
12. Microscopic endonasal transsphenoidal pituitary adenomectomy in the pediatric population.
Tarapore PE; Sughrue ME; Blevins L; Auguste KI; Gupta N; Kunwar S
J Neurosurg Pediatr; 2011 May; 7(5):501-9. PubMed ID: 21529190
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and medical treatment of male prolactinomas.
Asano S; Ueki K; Suzuki I; Kirino T
Acta Neurochir (Wien); 2001; 143(5):465-70. PubMed ID: 11482696
[TBL] [Abstract][Full Text] [Related]
14. Endonasal endoscopic transsphenoidal chiasmapexy using a clival cranial base cranioplasty for visual loss from massive empty sella following macroprolactinoma treatment with bromocriptine: case report.
Alvarez Berastegui GR; Raza SM; Anand VK; Schwartz TH
J Neurosurg; 2016 Apr; 124(4):1025-31. PubMed ID: 26339851
[TBL] [Abstract][Full Text] [Related]
15. Contemporary management of prolactinomas.
Liu JK; Couldwell WT
Neurosurg Focus; 2004 Apr; 16(4):E2. PubMed ID: 15191331
[TBL] [Abstract][Full Text] [Related]
16. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
17. Transsphenoidal microsurgical results of female patients with prolactinomas.
Ikeda H; Watanabe K; Tominaga T; Yoshimoto T
Clin Neurol Neurosurg; 2013 Sep; 115(9):1621-5. PubMed ID: 23498159
[TBL] [Abstract][Full Text] [Related]
18. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
19. An Economic Analysis of Bromocriptine Versus Trans-Sphenoidal Surgery for the Treatment of Prolactinoma.
Duan L; Yan H; Huang M; Zhang Y; Gu F
J Craniofac Surg; 2017 Jun; 28(4):1046-1051. PubMed ID: 28145933
[TBL] [Abstract][Full Text] [Related]
20. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
